Teresa S. Latham, DrPH, PhD

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea. Backeljauw, P; Tomlinson, G; Smart, LR; Tshilolo, L; Williams, TN; Santos, B; Olupot-Olupot, P; Stuber, S; Lane, A; Latham, T; Ware, RE. Blood advances. 2026; 10(13):4483-4494.

High early mortality among Ugandan children with sickle cell anemia and congenital HIV identified by newborn screening. Latham, TS; Kiyaga, C; Hernandez, AG; Nakafeero, M; Kadde, N; Stuber, SE; Ndeezi, G; Aceng, JR; Ware, RE. Blood Glob Hematol. 2026; 2(2):100093.

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial. Ambrose, EE; Tomlinson, G; Ngoya, PS; Stuber, SE; Latham, TS; Ware, RE; Makubi, AN; Smart, LR. Acta Haematologica. 2026; 1-11.

Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. Power-Hays, A; Mcelhinney, KE; Williams, TN; Mochamah, G; Olupot-Olupot, P; Paasi, G; Reid, ME; Rankine-Mullings, AE; Opoka, RO; John, CC; Stuber, SE; Latham, TS; Vinks, AA; Ware, RE. Blood advances. 2026; 10(2):418-427.

Development of disease-specific growth curves from Kenyan children with sickle cell anemia. Tomlinson, GA; Backeljauw, P; Mochamah, G; Smart, LR; Latham, TS; Ware, RE; Williams, TN. Blood Glob Hematol. 2025; 1(3):100031.

Full assessment of clinical transfusion support (FACTS): A prospective Study to determine the burden of sickle cell anemia on pediatric blood transfusion use in a malaria-endemic region in Africa. Power-Hays, A; Namazzi, R; Mcelhinney, K; Kincaid, A; Kato, C; Aliwuya, S; Opoka, R; Conroy, A; John, C; Hume, HA; Stuber, S; Latham, T; Ware, R. Blood. 2025; 146(Supplement 1):300-300.

Health status of Ugandan children born with sickle cell anemia and congenital HIV identified through newborn screening. Latham, T; Kiyaga, C; Hernandez, A; Nakafeero, M; Kadde, N; Khainza, P; Stuber, S; Ndeezi, G; Aceng, J; Ware, R. Blood. 2025; 146(Supplement 1):2668.

Measles vaccine-induced sero-protection among children with sickle cell anemia. Power-Hays, A; Kincaid, A; Mcelhinney, K; Latham, T; Quinn, C; Frenck, R; Ware, R. Blood. 2025; 146(Supplement 1):1168.

Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Grimley, M; Davies, SM; Shrestha, A; Shova, A; Asnani, M; Kent, M; Sayani, F; Quinn, CT; Niss, O; Lutzko, C; Witting, S; Latham, T; Bushman, FD; Malik, P. Nature Medicine. 2025; 31(7):2204-2212.

The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. Power-Hays, A; Namazzi, R; Dong, M; Kazinga, C; Kato, C; Aliwuya, S; Mcelhinney, K; Conroy, AL; Lane, A; John, C; Vinks, AA; Latham, T; Opoka, RO; Ware, RE. British Journal of Clinical Pharmacology. 2025; 91(6):1865-1872.